InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,634.61
(
1.15%
)
US TECH 100
19,231.20
(
0.16%
)
Dow Jones
41,175.08
(
1.14%
)
Brent Oil
79.12
(
0.95%
)
Bitcoin
63,780.01
(
-0.90%
)
Post# of 252971
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120332
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 94826

Tuesday, 04/27/2010 2:48:03 PM

Tuesday, April 27, 2010 2:48:03 PM

Post# of 252971

Gilead anticipates submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the fixed-dose combination following validation of the TMC278 NDA.

The word validation is needlessly obfuscating, IMO. GILD is saying that it will submit the NDA for the TMC278+Truvada combo pill when the FDA accepts JNJ’s TMC278 NDA for review, which should be about two months after JNJ submits the TMC278 NDA.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up